



Market Announcement

5 March 2020

Medlab Clinical Limited (ASX: MDC) – Trading Halt

Description

The securities of Medlab Clinical Limited ('MDC') will be placed in trading halt at the request of MDC, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Monday, 9 March 2020 or when the announcement is released to the market.

Issued by

Corey Lian

Adviser, Listings Compliance (Sydney)



5 March 2020

Corey Lian
Australian Securities Exchange
Exchange Centre
20 Bridge Street
Sydney, NSW 2000

By email: tradinghaltssydney@asx.com.au
corey.lian@asx.com.au

Dear Corey

REQUEST FOR TRADING HALT

In accordance with ASX Listing Rule 17.1, Medlab Clinical Limited (the Company) (ASX: MDC), requests a trading halt for its ordinary shares as follows:

- The trading halt is requested pending an announcement in relation to the release of the results from the NanaBis™ advanced cancer pain trial conducted at Royal North Shore Hospital, Sydney, Australia.
- The Company requests the trading halt is to remain in place until the earlier of:
 - An announcement is made in relation to the outcome of the Trial; or
 - The commencement of trading on Monday 9 March 2020.
- The Company is not aware of any reason why the trading halt should not be granted.
- The Company is not aware of any other information necessary to inform the market about the trading halt.

For and behalf of the Board.

Alan Dworkin
Company Secretary